1. Factors Affecting Implant Length in Primary Inflatable Penile Prosthesis Placement.
- Author
-
Miller JA, Hammad M, Amini E, Andrianne R, Burnett AL, Gross K, Gross MS, Hatzichristodoulou G, Hotaling J, Hsieh TC, Jenkins LC, Jones JM, Lentz A, Levy J, Modgil V, Osmonov D, Park SH, Pearce I, Perito P, Sadeghi-Nejad H, Sempels M, Simhan J, Suarez-Sarmiento A Jr, van Renterghem K, Warner JN, Yafi FA, Ziegelmann M, and Barham DW
- Subjects
- Humans, Male, Retrospective Studies, Middle Aged, Aged, Erectile Dysfunction surgery, Prostatectomy methods, Penile Prosthesis, Penile Implantation methods, Prosthesis Design
- Abstract
Objective: To evaluate predictors of implant length for men undergoing primary IPP placement., Methods: A multicenter, retrospective cohort study was performed for men undergoing primary IPP placement at 16 high-volume surgical centers. Patient demographics, comorbidities, operative approach, and implanted cylinder and rear-tip extender length were recorded. Associations between potential preoperative and intraoperative predictors of total device length were tested using non-parametric correlation and Kruskal-Wallis tests, followed by multiple regression., Results: Of 3951 men undergoing primary IPP placement from July 2016 to July 2021, the median implant length was 20 cm (IQR: 19-22). Shorter implant length was associated with increasing age in years (β = -0.01, P = .009), Asian ethnicity (β = -2.34, P = .008), history of radical prostatectomy (β = -0.35, P = .001), and use of an infrapubic surgical approach (β = -1.02, P <.001). Black or African American ethnicity was associated with the implantation of longer devices (β = 0.35, P <.001). No significant associations were recorded with BMI, history of intracavernosal injections, diabetes mellitus, tobacco use, radiation therapy, Peyronie's disease, priapism, or cavernosal dilation technique., Conclusion: The length of an implanted penile prosthesis was found to be associated with preoperative and intraoperative factors including history of radical prostatectomy and operative approach. The knowledge of these associations may assist in the preoperative counseling of patients receiving IPP and help create accurate postoperative expectations., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: JAM, MH, EA, KG, GH, JMH, TH, JMJ, VM, SHP, IP, HSN, AS, MS, KVR, NW, DWB - no disclosures; MSG-consultant Coloplast; AL-speaker, consultant, preceptor for Boston Scientific and Coloplast; DO-consultant Coloplast, Intuitive Surgical, Fidelis; PP-consultant Coloplast. Boston Scientific, Urofill; JS-consultant Boston Scientific and Coloplast; FAY- consultant for Coloplast, Cynosure, Antares Pharma, Clarus Pharmaceuticals, Acerus Pharma; MZ- consultant Endo Pharma., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF